637 related articles for article (PubMed ID: 27989354)
21. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
[TBL] [Abstract][Full Text] [Related]
22. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
[TBL] [Abstract][Full Text] [Related]
23. Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Taneja SS
J Urol; 2017 Oct; 198(4):742-743. PubMed ID: 28905785
[No Abstract] [Full Text] [Related]
24. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
25. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
26. Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls.
Momozawa Y; Iwasaki Y; Hirata M; Liu X; Kamatani Y; Takahashi A; Sugano K; Yoshida T; Murakami Y; Matsuda K; Nakagawa H; Spurdle AB; Kubo M
J Natl Cancer Inst; 2020 Apr; 112(4):369-376. PubMed ID: 31214711
[TBL] [Abstract][Full Text] [Related]
27. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M
Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
29. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
30. Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Hemal S; DeWitt-Foy M; Klein EA
Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
[TBL] [Abstract][Full Text] [Related]
33. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
Fan Z; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Cancer Sci; 2019 Oct; 110(10):3368-3374. PubMed ID: 31432574
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
[TBL] [Abstract][Full Text] [Related]
35. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
[TBL] [Abstract][Full Text] [Related]
36. Repair-Gene Mutations Uncovered in Metastatic Prostate Cancer.
Cancer Discov; 2016 Sep; 6(9):OF3. PubMed ID: 27460689
[TBL] [Abstract][Full Text] [Related]
37. Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
Beebe-Dimmer JL; Zuhlke KA; Johnson AM; Liesman D; Cooney KA
Prostate; 2018 Apr; 78(5):321-326. PubMed ID: 29356034
[TBL] [Abstract][Full Text] [Related]
38. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
[TBL] [Abstract][Full Text] [Related]
39. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
40. Genomic and Clinicopathologic Characterization of
Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
